• Mashup Score: 5
    Common Sense Oncology – Outcomes That Matter - 10 month(s) ago

    Oncology needs a recalibrated approach that is more patient centred and prioritizes equitable cancer care. Our approach prioritizes patients’ needs, advocates for treatments that improve survival and quality-of-life, promotes informed decision making, and ensures these treatments are accessible to all…

    Source: commonsenseoncology.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Berninini
      Berninini

      🚨All Pharmacists! Common Sense Oncology is FREE to join and aligns with our common goal of prioritizing patient needs, outcomes that matter, and global access! https://t.co/orthhn1mP2 Everyone in @HOPArx, @ASHPOfficial, and the global #TwitteRx community should join! https://t.co/YThGAEPHaT

  • Mashup Score: 2
    FDA Approves Polatuzumab Vedotin Plus R-CHP for Previously Untreated DLBCL - 1 year(s) ago

    The FDA has approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone for use in adult patients who have previously untreated diffuse large B-cell lymphoma, not otherwise specified or high-grade B-cell lymphoma and who have an International Prognostic Index score of two or greater.

    Source: OncLive
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Berninini
      Berninini

      Pola+R-CHP approved for upfront DLBCL. However, no improvement in OS or QOL compared to standard R-CHOP. We’re talking about a 6.5% absolute difference in 2-year PFS here with a major increase in cost. This is a marginal gain, not a game changer 🤷🏻‍♂️ #lymsm https://t.co/1vDKr99UUR

  • Mashup Score: 2
    Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia - PubMed - 2 year(s) ago

    Prevention of relapse is a major therapeutic challenge and an unmet need for patients with acute myeloid leukemia (AML). Venetoclax is a highly selective, potent, oral BCL-2 inhibitor that induces apoptosis in AML cells. When combined with azacitidine, it leads to prolonged overall survival and rapi …

    Source: PubMed
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Berninini
      Berninini

      Have we not learned? Another global maintenance study in AML on its way: https://t.co/lzvg9nyI3K - PO aza + placebo vs. PO aza + ven - RFS is primary endpoint 😂 - Hopefully they give actual consolidation this time - missing placebo arm alone - Irrelevant for upfront aza/ven https://t.co/bzz5hk5UQf

  • Mashup Score: 1
    Episode 4: All Aboard the Oncology StewardSHIP by WolverHeme Happy Hour - 2 year(s) ago

    In this episode, Bernie Marini and Anthony Perissinotti are joined by two special guest hematology experts – Lydia Benitez, PharmD, BCOP, and Madeleine Ochs, PharmD, BCOP. Maddy and Lydia help us dive into the topic of Oncology Stewardship, including how we can incorporate Oncology Stewardship into practice to improve outcomes for patients.  Learn more about Oncology Stewardship in AML patients…

    Source: Anchor
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Berninini
      Berninini

      RT @WolverHeme: Episode 4 is out! "All Aboard the Oncology StewardSHIP". ⚓ https://t.co/e1fdCzyodz 🩸#wolverheme On this episode @ajperissi…

Load More